Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A research team at UT Southwestern Medical Center has discovered a cell-signaling mechanism instrumental in the most common brain cancer in adults. The discovery could lead to the development of therapeutics for the disease.
Subscribe to our email newsletter
Therapeutic drugs based on the research would target the epidermal growth factor receptor genes that play a major role in the development of deadly brain tumors, said the researchers, who reported their results in the journal Cancer Research.
The median survival of patients with glioblastoma multiforme (GBM), a cancer of the supportive tissue of the brain, currently is about one year after diagnosis with the best treatments available.
Researchers have known for years that tumor cells proliferate out of control by a mechanism characterized by an abnormally high number of copies of the epidermal growth factor receptor gene (EGFR). This overexpression of EGFR is a striking feature of GBM, present in 40% to 50% of tumors and results in an uncontrolled multiplication of both normal EGFR and a mutant form called EGFRvIII.
While studying human brain tumor tissue and human brain tumor cells from cell lines grown in the laboratory, the researchers discovered that EGFRvIII generates a unique pattern of signaling (distinct from normal EGFR) that causes brain cancer cells in GBM to grow and multiply unchecked.
“The better we understand the signaling mechanisms of the normal and the mutant EGFR, the better we can manipulate or control them,” said Dr Amyn Habib, assistant professor of neurology at UT Southwestern and the study's senior author. “Our findings suggest that you have to target both the mutant and the normal EGFR based on the mechanism we described.”